Zobrazeno 1 - 8
of 8
pro vyhledávání: '"David E. Stockett"'
Autor:
Rachael E Hawtin, David E Stockett, Jo Ann W Byl, Robert S McDowell, Tan Nguyen, Michelle R Arkin, Andrew Conroy, Wenjin Yang, Neil Osheroff, Judith A Fox
Publikováno v:
PLoS ONE, Vol 5, Iss 4, p e10186 (2010)
Topoisomerase II is critical for DNA replication, transcription and chromosome segregation and is a well validated target of anti-neoplastic drugs including the anthracyclines and epipodophyllotoxins. However, these drugs are limited by common tumor
Externí odkaz:
https://doaj.org/article/13467f009c0841b5998d831560bc564d
Autor:
Jeffrey W. Jacobs, Shannon O. Harris, W. Michael Flanagan, Joni W. Lam, Ute Hoch, Sean Ritchie, Raymond V. Fucini, Stig Hansen, Marc J. Evanchik, David E. Stockett, Brian J. Belmont, Jeffrey A. Silverman, Kristin M. Zimmerman, Hashash Ahmad, Pietro Taverna, Jennifer N. Hogan, Juli N. Teague, Jennifer P. Arbitrario, Anthony Howlett, Michael J. Romanowski
Publikováno v:
Cancer Chemotherapy and Pharmacology. 65:707-717
The Aurora family of serine/threonine kinases (Aurora-A, Aurora-B, and Aurora-C) plays a key role in cells orderly progression through mitosis. Elevated expression levels of Aurora kinases have been detected in a high percentage of melanoma, colon, b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10f55f64b155510603db6969a00c09da
https://doi.org/10.1007/s00280-009-1076-8
https://doi.org/10.1007/s00280-009-1076-8
Autor:
Bruce Fahr, Yafan Lu, Iana Serafimova, David E. Stockett, Phuongly Pham, Junfa Fan, Ingrid C. Choong, Duncan Walker, Ute Hoch, Sravanthi Cheeti, Erica Chan, Michelle R. Arkin
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:5763-5765
The identification of a selective CDK2, 7, 9 inhibitor 4 with improved permeability is described. Compound 4 exhibits comparable CDK selectivity profile to SNS-032, but shows improved permeability and higher bioavailability in mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::303937ba3989812bb0cb962ae59184ed
https://doi.org/10.1016/j.bmcl.2008.09.073
https://doi.org/10.1016/j.bmcl.2008.09.073
Autor:
Wenjin Yang, Jo Ann W. Byl, Neil Osheroff, Andrew Conroy, Rachael E. Hawtin, Judith A. Fox, David E. Stockett, Robert S. McDowell, Nguyen Tan, Michelle R. Arkin
Publikováno v:
PLoS ONE, Vol 5, Iss 4, p e10186 (2010)
PLoS ONE
PLoS ONE
Background Topoisomerase II is critical for DNA replication, transcription and chromosome segregation and is a well validated target of anti-neoplastic drugs including the anthracyclines and epipodophyllotoxins. However, these drugs are limited by co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c043b7175c253ce194513b9857017e5
http://europepmc.org/articles/PMC2855444?pdf=render
http://europepmc.org/articles/PMC2855444?pdf=render
Autor:
Rachael E. Hawtin, Ute Hoch, Michelle R. Arkin, David E. Stockett, Duncan Walker, Andrew Conroy, Judith A. Fox
Publikováno v:
Cancer chemotherapy and pharmacology. 64(4)
SNS-032 (formerly BMS-387032) is a potent, selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9, currently in phase 1 clinical trial for chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). We used the MM cell line RPMI-8226 to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1812a561e61d40e04654b1313b8c2f0
https://pubmed.ncbi.nlm.nih.gov/19169685
https://pubmed.ncbi.nlm.nih.gov/19169685
Autor:
Bruce Fahr, Junfa Fan, Duncan Walker, Sravanthi Cheeti, Ute Hoch, Erica Chan, Phuongly Pham, Ingrid C. Choong, Yafan Lu, Iana Serafimova, David E. Stockett
Publikováno v:
Bioorganicmedicinal chemistry letters. 18(23)
Modifications of the isonipecotic acid fragment of SNS-032 results in analogs which are more permeable and lower effluxed than SNS-032. The enantiomerically pure synthesis and the in vivo profile of analog 20 is described.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8da9bc8309e1c73e79a6b57e6f045ab0
https://pubmed.ncbi.nlm.nih.gov/18926699
https://pubmed.ncbi.nlm.nih.gov/18926699
Autor:
Jeffrey A. Silverman, Carrie D. Scatena, Rachael E. Hawtin, Jeffrey L. Kumer, David E. Stockett, Judith A. Fox
Publikováno v:
Molecular Cancer Therapeutics. 8:C222-C222
Voreloxin is a first-in-class anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II (Stockett et al. and Hawtin et al., AACR 2008). This leads to replication-dependent, site-selective DNA double strand breaks (DSB) target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cb5b85d00b966e46e1f8a0966f5b52e
https://doi.org/10.1158/1535-7163.targ-09-c222
https://doi.org/10.1158/1535-7163.targ-09-c222
Autor:
Thomas Helleday, Cecilia Lundin, David E. Stockett, Oi Kwan Wong, Rachael E. Hawtin, Judith A. Fox
Publikováno v:
Karolinska Institutet
Oncotarget
Oncotarget
Vosaroxin (formerly voreloxin) is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, inducing site-selective double-strand breaks (DSB), G2 arrest and apoptosis. Objective responses and complete remi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee10a1e75bb43874963558a306235eed
http://www.ncbi.nlm.nih.gov/pubmed/21317456
http://www.ncbi.nlm.nih.gov/pubmed/21317456
